US 2005/0239889 A1Published application

In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration

OwnerJean Gosselin, Louis Flamand +1inventors

InventorsJean Gosselin, Louis Flamand, Pierre Borgeat

Life of this patent

Estimating the term…

Abstract

The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.

Claims16

Dependent claims

A method for stimulating or increasing in vivo release of an α-defensin or MIP-1β in a human or animal comprising administering to a human or animal, a therapeutically effective amount of an exogenous LTB4 agent.

Dependencies are inferred from the claim text.

Facts

Application: 11/114,899Filed 26 Apr 2005
Priority: 26 Apr 2004
Published: 27 Oct 2005
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/232
Of acids having a carboxyl group bound to a chain of seven or more carbon atoms: having three or more double bonds, e.g. etretinate
A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids
A61K 31/202
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: having three or more double…
A61K 31/41
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with two or more ring hetero atoms, at least…

Family

Application60/564,947Us provisional application · filed 26 Apr 2004
US 2005/0239889 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results